Mental health, bias, and trauma shape sexual health visits, and histories should assess function, not just risk, according to Sameena Rahman, MD.
|Videos|August 6, 2020
Diversity and inclusion: How can ob/gyns ensure these practices are being implemented from the top down?
When asked how ob/gyns can make sure diversity and inclusion practices happen in their own practices, Drs. Vanessa Rogers and Shawna Nesbitt of UT Southwestern made it simple.
Advertisement
“Begin with self-reflection: Who are you? What do you know? What don’t you know? Be willing to admit that there are things you do not know. Work to fill that deficit.”
Watch the full extended interview with Drs. Rogers and Nesbitt, and stay tuned for their commentary piece in our August issue.
Advertisement
Related to this article
Samples from a large UK screening trial supported validation of the investigational Evident ovarian cancer test, according to Dawn Mattoon, PhD.
Late recurrence, high-risk features, and treatment failure can signal midlife night sweats aren’t menopause, according to Cheryl Cox Kinney, MD.
Menopausal brain fog is common, and hormone therapy has neutral cognitive effects, according to Pauline M. Maki, PhD.
Distress, not low libido alone, defines HSDD, which requires a biopsychosocial evaluation, according to Holly N. Thomas, MD, MS.
In the premiere episode of Mind, Body, & the Pause, Soma Mandal, MD, is joined by Manisha Parulekar, MD, and Jocelyn Carlo, MD, FACOG, to discuss the stages of the menopause transition.
This FAQ summarizes a Special Report discussion on off-label testosterone dosing, application, cost, and lab monitoring in women.
This FAQ summarizes a Special Report discussion on how two experts decide who is a candidate for testosterone therapy in women, from symptoms and context to hormone state vs age.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Centers for Medicare, Medicaid Services includes AMA's obstetric codes in 2027 fee schedule
2
FAQ: How is off-label testosterone dosed and monitored in women?
3
Q&A: Soma Mandal, MD, MSCP, on FDA boxed warning removals for MHT
4
FAQ: Who is a candidate for testosterone therapy in women?
5